Danaher stock holds near $207 after Q2 beat

Published on 09/08/2026 at 20:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Danaher stock is trading near recent highs after July 20, 2026 results showed revenue of $6.26 billion and EPS of $1.94.

Schwarz-Weiß-Reportagefoto eines Forschers am Mikroskop in einem klassischen Diagnostiklabor — Danaher Corp. Diagnostik-Labor US2358511028 in dokumentarischer Schwarzweiß-Reportage mit Forscher am alten Mikroskop, Illustration mit AI erstellt.

Danaher Corp. (US2358511028) stock closed at USD 207.46 on September 4, 2026, after a 0.5 percent decline, while the 52-week range still stretched from USD 160.93 to USD 242.80. The latest trading snapshot also put the market value at USD 145.84 billion and daily volume in the hands of active investors, framing the stock around a mid-range valuation level.

July 20 still sets the tone

The core operating reference remains the July 20, 2026 quarter, when Danaher reported revenue of USD 6.26 billion and EPS of USD 1.94, both above the consensus estimates cited by MarketBeat. Revenue rose 5.5 percent year over year, while EPS was up from USD 0.77 in the same quarter of 2025, a jump that shows how sharply profitability improved. Net margin reached 15.95 percent in that report.

That combination matters because the stock is still being judged less by the absolute size of the quarter than by the mix: higher earnings, a modest top-line beat and a valuation that remains below the 52-week high. MarketBeat also put the average analyst rating at Moderate Buy with an average price target of USD 228.91, leaving the shares below the street average.

Analysts keep the bar high

Several houses updated their views in the recent coverage window, including MarketBeat, which highlighted a price target cluster that included RBC at USD 215, Deutsche Bank at USD 240 and TD Cowen at USD 236. The same report said Danaher had a P/E ratio of 36.85 and a PEG ratio of 2.59, so valuation remains part of the debate alongside earnings quality.

For investors, the key comparison is simple: the July quarter delivered USD 1.94 EPS versus USD 1.85 expected, but the stock still finished September 4 below the USD 228.91 consensus target. That gap leaves execution and margin follow-through as the main focus.

Life sciences still drives scale

Danaher's portfolio in life sciences, diagnostics and environmental and applied markets remains the operating backbone, with instruments, reagents and software as the main revenue builders. In the latest quarter, the company also reported return on equity of 11.04 percent, giving a second profitability marker alongside the 15.95 percent net margin.

Near the 52-week band

Danaher stock ended September 4 at USD 207.46 on NYSE, well above the USD 160.93 low and below the USD 242.80 high for the past year. The current setup leaves the shares in the middle of that band, with the July 20 earnings beat and the USD 228.91 analyst target providing the main reference points for the next move.